سعر الكابرس تريو 5/160/25مجم 14 قرص 2024

Fixed-dose triple antihypertensive combination tablet (Hikma Pharma) containing amlodipine 5 mg, valsartan 160 mg and hydrochlorothiazide 25 mg; 14 film-coated tablets.

• Hypertension, to lower blood pressure (reduces risk of fatal and non-fatal cardiovascular events); for patients not adequately controlled on any 2 of: calcium channel blockers, ARBs and diuretics, or as substitution for individually titrated componentsPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Adverse reactions reported more often than with dual combinations: dizziness, peripheral oedema, headache, dyspepsia, fatigue, muscle spasms, back pain, nausea and nasopharyngitis.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hydrochlorothiazide is associated with an increased risk of non-melanoma skin cancer (predominantly squamous cell carcinoma, mainly in white patients taking large cumulative doses); patients should protect skin from the sun and undergo regular skin cancer screening.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Anuria.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to other sulfonamide-derived drugs.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Known hypersensitivity to any component of the product.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning - fetal toxicity: drugs acting on the renin-angiotensin system can cause injury and death to the developing fetus; discontinue as soon as possible when pregnancy is detected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypotension in volume- or salt-depleted patients; correct depletion before starting.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Increased angina or acute myocardial infarction may occur on starting or increasing the dose of amlodipine, particularly in severe obstructive coronary artery disease.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• CYP3A inhibitors (moderate and strong)Increase amlodipine exposure; may require dose reduction - monitor for hypotension and oedema.DailyMed (U.S. National Library of Medicine)
• CYP3A inducersEffect on amlodipine not quantified; monitor blood pressure closely.DailyMed (U.S. National Library of Medicine)
• SildenafilMonitor for hypotension when co-administered with amlodipine.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm: use of drugs acting on the renin-angiotensin system during the second and third trimesters reduces fetal renal function and increases fetal and neonatal morbidity and death. Discontinue as soon as possible when pregnancy is detected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hydrochlorothiazide is present in human milk, amlodipine has been reported in human milk and valsartan is present in rat milk; because of potential serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Amlodipine: Inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, acting as a peripheral arterial vasodilator.
• Valsartan: Blocks the vasoconstrictor and aldosterone-secreting (sodium-retaining) effects of angiotensin II at the AT1 receptor.
• Hydrochlorothiazide: Promotes renal excretion of sodium and chloride, reducing intravascular volume.